You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Novel Antipsychotic Therapies: A Review of Non-D2 Mechanisms and Implications for Care

  • Authors: Leslie Citrome, MD, MPH​; Deanna L. Kelly, PharmD, BCPP; Diana O. Perkins, MD, MPH
  • CME / ABIM MOC Released: 1/17/2023
  • Valid for credit through: 1/17/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for psychiatrists, primary care physicians, critical care specialists, nurse practitioners (NPs), physician assistants (PAs), nurses, pharmacists, and other healthcare professionals (HCPs) who provide care to patients with schizophrenia.

The goal of this activity is for learners to be better able to recognize the role of nondopamine mechanisms in the development of emerging and novel therapeutics in schizophrenia and the current status of clinical studies of compounds that target these mechanisms.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Mechanism of trace amine-associated receptor 1 (TAAR1) as a therapeutic target for schizophrenia treatment
    • Involvement of serotonin in psychosis
    • Involvement of acetylcholine and related receptors in psychosis


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


  • Leslie Citrome, MD, MPH

    Clinical Professor​
    Psychiatry and Behavioral Sciences​
    New York Medical College​
    Valhalla, New York


    Leslie Citrome, MD, MPH, has the following relevant financial relationships:
    Consultant or advisor for: ​AbbVie, Inc./Allergan; ACADIA Pharmaceuticals Inc.; Adamas Pharmaceuticals, Inc.; Alkermes, Inc.; Angelini; Astellas Pharma, Inc.; Avanir Pharmaceuticals; Axsome Therapeutics, Inc.; BioXcel Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Cadent Therapeutics; Cerevel; Clinilabs; COMPASS; Eisai, Inc.; Enteris BioPharma; HLS Therapeutics; Impel; Idorsia; INmuneBIO; Intra-Cellular Therapies; Janssen; Karuna; Lundbeck; Lyndra; Medavante-ProPhase; Marvin; Merck; Mitsubishi-Tanabe Pharma; Neurocrine; Neurelis, Inc.; Novartis; Noven; Otsuka; Ovid; Praxis; Recordati; Relmada; Reviva; Sage; Sunovion; Supernus; Teva 
    Speaker or member of speakers bureau for: AbbVie, Inc./Allergan; ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Angelini; Eisai, Inc.; Intra-Cellular Therapies, Inc.; Janssen; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Sage Therapeutics, Inc.; Sunovion Pharmaceuticals Inc.; Takeda; Teva  
    Stock options from: ​Reviva​ Pharmaceuticals Inc. 
    Owns stock (publicly traded) in: Bristol Myers Squibb Company; Eli Lilly; Johnson & Johnson; Merck; Pfizer, Inc.  

  • Deanna L. Kelly, PharmD, BCPP

    MPower Professor of Psychiatry  ​
    University of Maryland Strategic Partnership: MPowering the State  ​
    University of Maryland School of Medicine ​
    Baltimore, Maryland​


    Deanna L. Kelly, PharmD, BCPP, has the following relevant financial relationships:
    Consultant or advisor for: Alkermes, Inc. (former); Janssen; Sunovion Pharmaceuticals Inc. 
    Research funding from: Saladax Biomedical Inc. 

  • Diana O. Perkins, MD, MPH

    Department of Psychiatry ​
    University of North Carolina at Chapel Hill​
    Chapel Hill, North Carolina


    Diana O. Perkins, MD, MPH, has the following relevant financial relationships:
    Consultant or advisor for: Alkermes, Inc.; Karuna Therapeutics
    Contracted researcher for: Boehringer Ingelheim Pharmaceuticals, Inc. 


  • Lisette Arnaud-Hevi, PhD

    Medical Education Director, Medscape, LLC


    Lisette Arnaud-Hevi, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Novel Antipsychotic Therapies: A Review of Non-D2 Mechanisms and Implications for Care

Authors: Leslie Citrome, MD, MPH​; Deanna L. Kelly, PharmD, BCPP; Diana O. Perkins, MD, MPHFaculty and Disclosures

CME / ABIM MOC Released: 1/17/2023

Valid for credit through: 1/17/2024


A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

  • Print